Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590
Chemed Corporation
Chemed Corporation CHE | 0.00 |
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:
CHE) with a Outperform and raises the price target from $500 to $590.